148 related articles for article (PubMed ID: 37929603)
1. Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients With Atrial Fibrillation in the United States.
Sandhu A; Kaltenbach LA; Chiswell K; Shimoga V; Ashur C; Pribish A; Fonarow GC; Piccini JP; Ho PM; Varosy PD; Hess PL
Circ Cardiovasc Qual Outcomes; 2023 Dec; 16(12):e010062. PubMed ID: 37929603
[TBL] [Abstract][Full Text] [Related]
2. Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis.
Zhang XL; Zhang XW; Wang TY; Wang HW; Chen Z; Xu B; Xu W
Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e007971. PubMed ID: 34932377
[TBL] [Abstract][Full Text] [Related]
3. Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over.
Cavillon Decaestecker M; Ferret L; Decaestecker K; Gautier S; Verdun S; Tsogli ES
Drugs Aging; 2021 Oct; 38(10):939-950. PubMed ID: 34486094
[TBL] [Abstract][Full Text] [Related]
4. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation.
Chan YH; Chao TF; Chen SW; Lee HF; Yeh YH; Huang YC; Chang SH; Kuo CT; Lip GYH; Chen SA
Heart Rhythm; 2020 Dec; 17(12):2102-2110. PubMed ID: 32702416
[TBL] [Abstract][Full Text] [Related]
5. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
Briasoulis A; Gao Y; Inampudi C; Alvarez P; Asleh R; Chrischilles E; Leira EC; Vaughan-Sarrazin M
BMC Cardiovasc Disord; 2020 Feb; 20(1):42. PubMed ID: 32013886
[TBL] [Abstract][Full Text] [Related]
7. Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study.
Miyazaki M; Matsuo K; Uchiyama M; Nakamura Y; Sakamoto Y; Misaki M; Tokura K; Jimi S; Okamura K; Adachi S; Yamamoto T; Shirai K; Urata H; Imakyure O
J Pharm Health Care Sci; 2020; 6():2. PubMed ID: 32071730
[TBL] [Abstract][Full Text] [Related]
8. Determinants for under- and overdosing of direct oral anticoagulants and physicians' implementation of clinical pharmacists' recommendations.
Moudallel S; Cornu P; Dupont A; Steurbaut S
Br J Clin Pharmacol; 2022 Feb; 88(2):753-763. PubMed ID: 34331720
[TBL] [Abstract][Full Text] [Related]
9. Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation.
Li RJ; Caughey GE; Shakib S
J Thromb Thrombolysis; 2022 Feb; 53(2):425-435. PubMed ID: 34302286
[TBL] [Abstract][Full Text] [Related]
10. Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.
Khachatryan A; Doobaree IU; Spentzouris G; Gusto G; Zawaneh Y; Mughal F; Anastassopoulou A; Manu M; Fay M
Adv Ther; 2023 Feb; 40(2):504-520. PubMed ID: 36399317
[TBL] [Abstract][Full Text] [Related]
11. Off-label underdosing of four individual NOACs in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of observational studies.
Sang C; Chen J; Sun J; Lai Y; Liu X; Zhu W
Eur J Clin Invest; 2022 Oct; 52(10):e13819. PubMed ID: 35643840
[TBL] [Abstract][Full Text] [Related]
12. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing.
Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB
Am J Cardiol; 2020 May; 125(9):1332-1338. PubMed ID: 32098658
[TBL] [Abstract][Full Text] [Related]
13. Off-label direct oral anticoagulants dosing in atrial fibrillation and venous thromboembolism is associated with higher mortality.
Aguilar F; Lo KB; Quintero EE; Torres RJ; Hung WA; Albano JC; Alviz I; Rodriguez C; Garcia MJ; Romero J; Slipczuk L
Expert Rev Cardiovasc Ther; 2021 Dec; 19(12):1119-1126. PubMed ID: 34879208
[TBL] [Abstract][Full Text] [Related]
14. Modification of In-Hospital Recommendation and Prescription of Anticoagulants for Secondary Prevention of Stroke after Launch of Direct Oral Anticoagulants and Change of National Guidelines.
Gronemann C; Hause S; Assmann A; Neumann J; Schreiber S; Heinze HJ; Goertler M
Cerebrovasc Dis; 2020; 49(4):412-418. PubMed ID: 32756054
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies.
Chan YH; Chan CY; Chen SW; Chao TF; Lip GYH
Europace; 2023 Oct; 25(10):. PubMed ID: 37738425
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and risk of inappropriate dosing of direct oral anticoagulants in two Swiss atrial fibrillation registries.
Montrasio G; Reiner MF; Wiencierz A; Aeschbacher S; Baumgartner C; Rodondi N; Kühne M; Moschovitis G; Preiss H; Coslovsky M; De Perna ML; Bonati LH; Conen D; Osswald S; Beer JH; Koepfli P;
Vascul Pharmacol; 2022 Dec; 147():107120. PubMed ID: 36182083
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Oral Anticoagulant Dosing and Adherence to Therapy Among Patients With Nonvalvular Atrial Fibrillation.
Rymer JA; Chiswell K; Young L; Chiu A; Liu L; Webb L; Carlisle M; Friedman D; Wang TY
JAMA Netw Open; 2023 Jun; 6(6):e2317156. PubMed ID: 37285155
[TBL] [Abstract][Full Text] [Related]
18. Differences in Preferences Between Clinicians and Patients for the Use and Dosing of Direct Oral Anticoagulants for Atrial Fibrillation.
Rymer JA; Webb L; McCall D; Hills MT; Wang TY
J Am Heart Assoc; 2021 Jun; 10(11):e020697. PubMed ID: 33998252
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
Russo V; Cattaneo D; Giannetti L; Bottino R; Laezza N; Atripaldi U; Clementi E
Clin Ther; 2021 Sep; 43(9):e255-e263. PubMed ID: 34366151
[TBL] [Abstract][Full Text] [Related]
20. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
